Definium Therapeutics reported a sale by Chief Legal Officer Mark Sullivan of 10,702 common shares on March 25, 2026, according to a Form 4 filing. The shares were disposed of at a weighted average price of $18.47, producing proceeds of $197,665. Traded prices in the block ranged between $18.36 and $18.80.
Following the sale, Sullivan retains direct ownership of 271,079 shares of Definium Therapeutics. The filing states the disposition was executed to cover withholding tax liabilities associated with the settlement of vested restricted stock units. The trades were carried out pursuant to a pre-arranged Rule 10b5-1 trading arrangement that the officer adopted on March 14, 2024.
Separately, company disclosures for the fourth quarter of 2025 emphasize Definium's significant allocation of resources to research and development. The company singled out activity around its DT120 program as a notable element of its pipeline priorities. Despite reporting a material net loss for the quarter, Definium disclosed that it maintains a robust cash position, which management says supports continued advancement of its clinical programs and strategic initiatives.
The company did not report any merger or acquisition activity in the period, and there were no analyst upgrades or downgrades disclosed alongside the results. The combination of heavy R&D spend, a focus on a lead clinical program, and a strong cash balance has left the company's financials and strategic trajectory as points of investor attention.
Market observers reviewing the Form 4 will note the sale was structured via a 10b5-1 plan and was described as tax-related rather than an ad hoc trade. The filing provides specifics on share counts, price range, and resulting ownership that are relevant for stakeholders monitoring insider activity at the firm.
Contextual note - The details above are limited to the information disclosed in the company's filings and its fourth-quarter 2025 financial summary. Where the filing or results do not provide additional granularity, that limitation is reflected rather than supplemented.